华熙生物
(688363)
| 流通市值：118.75亿 | | | 总市值：288.62亿 |
| 流通股本：1.98亿 | | | 总股本：4.82亿 |
| 报告期 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 4,221,434,960.6 | 3,075,611,629.22 | 1,305,155,874.23 | 6,359,191,975.49 |
| 营业收入 | 4,221,434,960.6 | 3,075,611,629.22 | 1,305,155,874.23 | 6,359,191,975.49 |
| 二、营业总成本 | 3,695,744,556.37 | 2,625,933,511.09 | 1,120,138,044.48 | 5,322,193,479.66 |
| 营业成本 | 1,136,684,136.32 | 805,884,531.69 | 342,188,052.59 | 1,463,226,844.07 |
| 税金及附加 | 44,759,884.7 | 29,980,036.53 | 9,395,960.29 | 77,196,104.89 |
| 销售费用 | 1,942,502,310.2 | 1,420,217,921.56 | 605,505,558.16 | 3,049,366,727.62 |
| 管理费用 | 319,679,745.44 | 205,484,635.42 | 85,949,868.3 | 392,872,365.32 |
| 研发费用 | 277,108,880.65 | 186,700,314.21 | 83,153,130.85 | 388,187,957.66 |
| 财务费用 | -24,990,400.94 | -22,333,928.32 | -6,054,525.71 | -48,656,519.9 |
| 其中:利息费用 | 5,126,353.43 | 5,962,311.64 | 1,609,222.97 | 9,147,373.98 |
| 其中:利息收入 | 29,597,021.94 | 21,346,576.52 | 11,026,526.88 | 38,528,347.5 |
| 加:公允价值变动收益 | 236,066.67 | 260,750 | -185,858.74 | -142,577.22 |
| 加:投资收益 | 1,853,827.64 | 1,597,280.23 | 1,860,834.81 | 11,915,224.42 |
| 资产处置收益 | - | - | - | -488,680.41 |
| 资产减值损失(新) | -3,813,026.38 | -210,691.87 | 1,316,968.69 | -15,447,248.44 |
| 信用减值损失(新) | -11,355,516.33 | -10,158,885.5 | -4,178,280.61 | -18,710,674.89 |
| 其他收益 | 98,552,951.44 | 76,443,319.04 | 59,285,971.49 | 122,189,239.72 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 611,164,707.27 | 517,609,890.03 | 243,117,465.39 | 1,136,313,779.01 |
| 加:营业外收入 | 1,964,100.96 | 1,680,177.24 | 879,204.38 | 6,120,774.4 |
| 减:营业外支出 | 2,701,348.63 | 2,660,056.11 | 2,248,074.58 | 6,322,551.66 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 610,427,459.6 | 516,630,011.16 | 241,748,595.19 | 1,136,112,001.75 |
| 减:所得税费用 | 103,344,481.68 | 95,068,103.83 | 40,776,322.25 | 174,731,795.68 |
| 六、净利润 | 507,082,977.92 | 421,561,907.33 | 200,972,272.94 | 961,380,206.07 |
| 持续经营净利润 | 507,082,977.92 | 421,561,907.33 | 200,972,272.94 | 961,380,206.07 |
| 归属于母公司股东的净利润 | 514,400,873.54 | 424,608,695.6 | 200,485,364.45 | 970,918,593.78 |
| 少数股东损益 | -7,317,895.62 | -3,046,788.27 | 486,908.48 | -9,538,387.71 |
| (一)基本每股收益 | 1.07 | 0.88 | 0.42 | 2.02 |
| (二)稀释每股收益 | 1.07 | 0.88 | 0.42 | 2.01 |
| 八、其他综合收益 | 7,791,296.79 | 20,336,182.59 | -610,303.45 | 14,809,397.55 |
| 归属于母公司股东的其他综合收益 | 7,791,296.79 | 20,336,182.59 | -610,303.45 | 14,809,397.55 |
| 九、综合收益总额 | 514,874,274.71 | 441,898,089.92 | 200,361,969.49 | 976,189,603.62 |
| 归属于母公司股东的综合收益总额 | 522,192,170.33 | 444,944,878.19 | 199,875,061.01 | 985,727,991.33 |
| 归属于少数股东的综合收益总额 | -7,317,895.62 | -3,046,788.27 | 486,908.48 | -9,538,387.71 |
| 公告日期 | 2023-10-31 | 2023-08-30 | 2023-04-29 | 2023-03-31 |
| 审计意见(境内) | | | | 标准无保留意见 |